ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.92
-0.12%
US Tech 100
20,914.40
1.16%
S&P 500
6,083.44
0.55%
US Dollar vs CAD
1.40645
-0.02%
Bitcoin
98,362.20
2.49%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. IO Biotech Inc (IOBT)

  7. IO Biotech Inc (IOBT) News

IOBT

IO Biotech (IOBT)

IO Biotech Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IOBT
DateTimeSourceHeadlineSymbolCompany
11/12/20243:30PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IOBTIO Biotech Inc
11/12/20246:11AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
11/12/20246:05AMGlobeNewswire Inc.IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:IOBTIO Biotech Inc
11/11/20243:05PMGlobeNewswire Inc.IO Biotech Announces Participation in Upcoming Investor ConferencesNASDAQ:IOBTIO Biotech Inc
11/07/20249:00AMGlobeNewswire Inc.IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 StudyNASDAQ:IOBTIO Biotech Inc
10/04/20248:00AMGlobeNewswire Inc.IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingNASDAQ:IOBTIO Biotech Inc
09/14/20241:30AMGlobeNewswire Inc.IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck CancerNASDAQ:IOBTIO Biotech Inc
08/30/20243:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
08/30/20243:05PMGlobeNewswire Inc.IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced MelanomaNASDAQ:IOBTIO Biotech Inc
08/26/20243:05PMGlobeNewswire Inc.IO Biotech Announces Participation in Upcoming Investor ConferencesNASDAQ:IOBTIO Biotech Inc
08/13/20243:06PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IOBTIO Biotech Inc
08/13/20246:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
08/13/20246:05AMGlobeNewswire Inc.IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:IOBTIO Biotech Inc
07/25/20243:05PMGlobeNewswire Inc.IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024NASDAQ:IOBTIO Biotech Inc
06/11/20243:44PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
06/07/20243:18PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IOBTIO Biotech Inc
06/07/20243:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IOBTIO Biotech Inc
05/23/20247:30AMGlobeNewswire Inc.IO Biotech to Present at Jefferies Global Healthcare ConferenceNASDAQ:IOBTIO Biotech Inc
05/14/20247:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
05/14/20247:13AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IOBTIO Biotech Inc
05/14/20246:55AMGlobeNewswire Inc.IO Biotech Reports First Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:IOBTIO Biotech Inc
04/24/20243:30PMGlobeNewswire Inc.IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:IOBTIO Biotech Inc
04/15/20247:30AMGlobeNewswire Inc.IO Biotech Expands Senior Leadership Team to Progress Commercialization ReadinessNASDAQ:IOBTIO Biotech Inc
04/09/202411:00AMGlobeNewswire Inc.IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103NASDAQ:IOBTIO Biotech Inc
04/05/20247:30AMGlobeNewswire Inc.IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business OfficerNASDAQ:IOBTIO Biotech Inc
03/11/20243:56PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IOBTIO Biotech Inc
03/06/20243:11PMGlobeNewswire Inc.IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:IOBTIO Biotech Inc
03/05/20244:17PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:IOBTIO Biotech Inc
03/05/20243:46PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
03/05/20243:40PMGlobeNewswire Inc.IO Biotech Announces 2023 Fourth-Quarter and Year-End ResultsNASDAQ:IOBTIO Biotech Inc
 Showing the most relevant articles for your search:NASDAQ:IOBT

Your Recent History

USOTC
HMBL
HUMBL (PK)
USOTC
XERI
Xeriant (QB)
USOTC
NLST
Netlist (QB)
USOTC
RDGL
Vivos (QB)
USOTC
ZHUD
Zhuding (PK)
USOTC
CRTG
Coretec (QB)
USOTC
MONI
Moon Equity (PK)
USOTC
FNMA
Fannie Mae (QB)
USOTC
BIEL
Bioelectronics (PK)
AMEX
KULR
KULR Technology
NASDAQ
FCEL
FuelCell Energy
COIN
SHIBUSD
SHIBA INU
NASDAQ
RNAZ
TransCode Therapeutics
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
NYSE
IONQ
IonQ
USOTC
DBMM
Digital Brand Media and ... (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved